Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | FASN | P49327 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 5/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5688911 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL16149412 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL29403468 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL5688908 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL3423312 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL10538624 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL20866020 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL21638328 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL20866021 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL16149413 | 1.00 | TSHR (0.61) | TSHRALDH1A1FASNFAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507221-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | Aquinox Pharmaceuticals Inc. (CA) | 2012-10-10 | — | — | EP | disclosed |
| US-8101605-B2 | SHIP1 modulators and methods related thereto | AQUINOX PHARMACEUTICALS INC. (CA) | 2012-01-24 | — | — | US | disclosed |
| WO-2011069118-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136802-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | AQUINOX PHARMACEUTICALS INC. (CA) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136802-A1 | SHIP1 MODULATORS AND METHODS RELATED THERETO | PPM1D, PTPRO, PPM1G | TSHR 1013/4885ALDH1A1 1441/4885FASN 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.